Cabozantinib effective against prostate cancer at lower doses
Cabozantinib is as effective across four key metrics at doses of 40mg a day as it is at doses of 100mg, according to a new study.
Interim data from trials of patients with metastatic castration-resistant prostate cancer (CRPC) being treated with cabozantinib highlight the efficacy of the drug.
According to pharma giant Exelixis, those with CRPC and bone metastases receiving a 40mg daily dose of the drug in an ongoing non-randomised expansion cohort of phase two trials enjoy similar clinical results as those who previously received 100mg doses for several key parameters.
These include reduction of metastatic bone and soft tissue disease, as well as reduction of bonepain, with improved tolerability and fewer adverse reactions also witnessed as a result of the lower sdosages.
Dr Michael Morrissey, president and chief executive of the pharma company, explained that the results, presented at the European Society for Medical Oncology annual meeting in Austria, are consistent with interim data from a separate ongoing trial.
"The data suggest that the 40mg daily does has activity with respect to a number of key metrics, including bone and soft tissue responses, as well as changes in pain scores and narcotic use," he said. "Additionally, the 40mg dose appears to be well tolerated in patients with metastatic CRPC."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance